Drug Trial Radar · NCT02134301
Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections
Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
May 2014
Primary completion
Nov 4, 2025
Study completion Nov 4, 2025
Sponsor
- Lead sponsor
- Melinta Therapeutics, LLCIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1 trial is to evaluate the pharmacokinetics (PK), safety and tolerability of oritavancin in participants \<18 years old with a confirmed or suspected bacterial infection.
Conditions
- Gram-positive Bacterial Infections
Interventions
OritavancinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic Parameter (Area under the plasma concentration time-curve [AUC])Time frame: 336 hours post infusion start time for Cohorts 1-4 and 168 hours for Cohort 5
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital of Orange County
Orange, California
Rady Children's Hospital
San Diego, California
UCLA Harbor Medical Center
Torrance, California
Univ of Louisville, Norton Children's Research Institute
Louisville, Kentucky
University of Nebraska Medical Center
Omaha, Nebraska
Rainbow Babies and Children's Hospital
Cleveland, Ohio
Toledo Children's Hospital
Toledo, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.